Biological E Limited (BE) has opened a new unit. The new facility has been commissioned to increase the production of its existing portfolio of vaccines and manufacture new products.
The Rs 300 crore plant would employ around 1,000 people, according to the company. The company also unveiled its new Typhoid conjugate vaccine (TCV) on Monday.
BE recently received the authorisation from the Central Drugs Standard Control Organisation (CDSO) for the TCV, which was developed in partnership with GSK Vaccines Institute for Global Health.
According to BE managing director Mahima Datla, “We are happy that our joint efforts have successfully produced a promising Typhoid vaccine.
This is a remarkable milestone in our collaborative journey with the GSK Vaccines Institute for Global Health to save the maximum number of people, particularly children, around the world from Typhoid, which is a deadly, yet vaccine preventable disease.”
Image Credit : linkedin.com